



Quality For All

Tenth of Ramadan for Pharmaceutical Industries
and Diagnostic Reagents (Ramedda) S.A.E

Ramedda commences manufacture of “Anviziram” Tablets the Generic Equivalent of Japanese antiretroviral Avigan for treatment of Covid-19 patients and receives approval from Egyptian Drug Authority to manufacture Remdesivir

June 2020 | Cairo, Egypt

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents SAE (Ramedda), RMDA.CA on the EGX, a leading Egyptian pharmaceutical company, announced today that it has commenced the manufacture of Anviziram. Anviziram contains the active pharmaceutical ingredient Favipiravir, which is the generic form of the antiretroviral sold under the brand name Avigan in Japan. Ramedda has also secured approval from Egyptian Drug Authority to begin manufacturing intravenous “Remdesivir” vials for use in the treatment of patients suffering from coronavirus disease 2019 (Covid-19).

“Avigan” is an antiretroviral drug developed by Toyama Chemicals, a division of the Japanese conglomerate Fujifilm, and contains the active ingredient Favipiravir. Avigan has been administered to covid-19 patients in clinical studies. Favipiravir is believed to combat covid-19 by inhibiting viral reproduction, with studies indicating that the drug assists in stabilizing viral reproduction four to six days from first use.

It is worth noting that the Ministry of Higher Education and Scientific Research and the Ministry of Health and Population have performed clinical trials to determine the efficacy of a range of possible treatments, including Favipiravir, for Covid-19. Favipiravir has been used for experimental treatment of Covid-19 and clinical trials in China, Italy, Japan, and Russia. The Russian Health Ministry has approved a generic version of the drug for use in hospital settings, making Russia the first country to permit such use of Favipiravir.

“Ramedda is honoured to devote its capabilities and resources to serving the Egyptian people during this unique moment in world history,” said Dr. Amr Morsy, CEO of Ramedda. “We would like to express our deep appreciation for the efforts carried out by the Ministry of Health and Population and the Egyptian Drug Authority. Ramedda extends its heartfelt gratitude to His Excellency the Minister of Higher Education Dr. Khaled Abdel Ghaffar, Dr. Mohamed Awad Tageldin, advisor to President Abdel Fattah El Sisi for public health, Head of the Egyptian Drug Authority Research Dr. Tamer Essam, and to Head of the Egyptian Authority for Unified Procurement General Bahaa Zidan. We further wish to thank the Egyptian Ministry of Foreign Affairs and Mr. Ayman Kamel, Egypt’s Ambassador to Japan, as well as Dr. Hani



Quality For All

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Ramedda) S.A.E

Salim, Assistant to the Minister of Foreign Affairs for Asia. Our valued colleagues at the Ministry of Health cleared this molecule's path to manufacture in record time and facilitated our path through any obstacles to rapid approval and production at Egyptian facilities. Our thoughts and prayers are with the doctors, healthcare professionals and pharmacists on the front lines of this pandemic and with those who are suffering from the disease."

Ramedda's entire production of Favipiravir is being produced under the trade name Anviziram, with capacity focused on the Egyptian market. The company aims to export Anviziram to neighbouring countries upon receipt of approval from the Ministry of Health and the Egyptian Drug Authority.

In addition to Anviziram, Ramedda has been granted Egyptian Drug Authority's approval for the manufacture of intravenous Remdesivir, a broad-spectrum antiviral medication which has been used in treatment of covid-19 patients. The company aims to commence production of Remdesivir over the coming period.

-Ends-

Investor Relations Contact:

Yasmine Negm
Ramedda's Head of Strategic
Communications & Investor Relations
Email: yasmine.negm@rameda.com
Mobile: +20(0)1228505050

About Ramedda

Established in 1986, Ramedda (RMDA.CA on EGX) is a leading Egyptian pharmaceutical company led by a team of professionals with extensive multinational experience. The company develops and produces a wide range of branded generic pharmaceuticals, nutraceuticals, food supplements and veterinary products. Ramedda combines global standards with local insights and a customer-centric approach. It has developed a broad portfolio of products across multiple therapeutic areas, by successfully leveraging its strong product portfolio with its accretive product acquisitions to become one of the fastest-growing pharmaceutical players in Egypt. The company produces its wide range of dosage forms at its three manufacturing facilities located at the industrial complex in Cairo's Sixth of October Industrial Zone.

Forward-Looking Statements



This communication contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as “according to estimates”, “anticipates”, “assumes”, “believes”, “could”, “estimates”, “expects”, “intends”, “is of the opinion”, “may”, “plans”, “potential”, “predicts”, “projects”, “should”, “to the knowledge of”, “will”, “would”, or, in each case, their negatives, or other similar expressions that are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding our business and management, our future growth or profitability and general economic and regulatory conditions and other matters affecting us.

Forward-looking statements reflect our management’s (“Management”) current views of future events, are based on Management’s assumptions, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. The occurrence or non-occurrence of an assumption could cause our actual financial condition and results of operations to differ materially from, or fail to meet expectations expressed or implied by, such forward-looking statements. Our business is subject to a number of risks and uncertainties that could also cause a forward-looking statement, estimate, or prediction to become inaccurate. These risks include fluctuations in the prices of raw materials or employee costs required by our operations, its ability to retain the services of certain key employees, its ability to compete successfully, changes in political, social, legal, or economic conditions in Egypt, worldwide economic trends, the impact of war and terrorist activity, inflation, interest rate and exchange rate fluctuations, and Management’s ability to timely and accurately identify future risks to our business and manage the risks mentioned above.

Certain figures contained in this document, including financial information, have been subject to rounding adjustments. Accordingly, in certain instances, the sum or percentage change of the numbers contained in this document may not conform exactly to the total figure given.